Severe Malaria Due To Plasmodium Falciparum Therapeutics
1. Artesunate patent expiration
Treatment: A method of treating malaria using micronized powder of crystalline artesunate prepared by sterilizing and filling the powder into a container at a relative humidity of 30 to 40%, mixing the powder wi...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12121506 | AMIVAS | Artesunate powders, pharmaceutical compositions and methods of manufacture |
Feb, 2044
(17 years from now) | |
| US12390442 | AMIVAS | NA |
Feb, 2044
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 26, 2025 |
| Orphan Drug Exclusivity(ODE-290) | May 26, 2027 |
Drugs and Companies using ARTESUNATE ingredient
NCE-1 date: 26 May, 2024
Market Authorisation Date: 26 May, 2020
Dosage: POWDER
More Information on Dosage
ARTESUNATE family patents
